Loading
When the tumour shows little PD-L1, immunotherapy alone is weak, but adding chemotherapy makes it work for most patients.
This combination gives a PD-1 checkpoint inhibitor together with cytotoxic chemotherapy in non-small-cell lung cancer whose PD-L1 tumour proportion score is low. Chemotherapy releases tumour antigen and depletes suppressive cells, priming an immune response that PD-1 blockade then sustains, and the benefit does not depend on the PD-L1 level. KEYNOTE-189 in non-squamous and KEYNOTE-407 in squamous disease showed an overall survival benefit across PD-L1 strata, including tumours with essentially no PD-L1 expression. POSEIDON adds tremelimumab to durvalumab and chemotherapy for PD-L1-negative and STK11- or KEAP1-mutant disease. Pembrolizumab with chemotherapy is now the standard control arm against which every new first-line lung regimen is measured.
Shares KEYNOTE-024 & KEYNOTE-189, Tumour proportion score (TPS), PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab.
Shares Tremelimumab, Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tremelimumab, Durvalumab, Pembrolizumab, Immune checkpoint inhibitors.
Shares Tremelimumab, Durvalumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/